

LEADING EDGE UROLOGY

47th DUKE UROLOGIC ASSEMBLY and DUKE UROLOGIC CANCER SYMPOSIUM
March 5 – 8, 2015

Accommodations

Join us at Disney's flagship convention hotel, the **Grand Floridian**, where modern meets Victorian, transporting and immersing our conference guests in the graciousness of a bygone era.

See the link below to visit our custom site for all of your planning needs for your upcoming meeting at Disney.
<http://www.mydisneymeetings.com/2015-duke-urologic-assembly/>

Group rates: Rooms are being held for this conference at a nightly room rate of \$265 (single/double) plus applicable taxes (currently 12.5%) until February 3, 2015 or until the block is full. After the block is full or the cut-off date, reservations will be subject to availability and prevailing room rates. Subject to availability, rooms can be reserved at this group rate for three days before and three days after the meeting dates. Check-in time is 3:00 p.m. and check-out is 11:00 a.m. Complimentary Magical Express airport transfers are included in room rate. **Hotel reservations can be made by calling 407-939-4686.**



First Class Mail
US Postage
PAID
Permit No. 60

CONFERENCE REGISTRATION

Leading Edge Urology: Duke Urologic Cancer Symposium

9.75 AMA Credits • Thursday & Friday (2 day conference)

\$350.00 Physician/Scientist Tuition

Registration includes Syllabus, Breaks, Thursday Reception, and Friday Breakfast and Luncheon

\$200.00 Advanced Practice Providers Tuition (PA, NP, RN)

Registration includes Syllabus, Breaks, Thursday Reception, and Friday Breakfast and Luncheon

Leading Edge Urology: Duke Urologic Cancer Symposium and Duke Urologic Assembly

19.5 AMA Credits • Thursday – Sunday (4 day conference)

\$575.00 Early Bird Physician/Scientist Tuition

Register before February 13, 2015 for the early bird registration. Early Registration to four day conference includes Syllabus, Thursday Reception, three Breakfasts, Breaks, and Friday Luncheon

\$625.00 Physician/Scientist Tuition starting February 13, 2015

\$400.00 Advanced Practice Providers Tuition (PA, NP, RN)

Registration to four day conference includes Syllabus, Thursday Reception, three Breakfasts, Breaks, and Friday Luncheon.

Guests of registered attendees are invited to attend the Welcome Reception, Breakfasts, and Luncheon for an additional \$75.00 for adults and children (age 13 and over) and must be paid at registration.

CONFERENCE WEBSITE

<http://urology.surgery.duke.edu>

CANCELLATION POLICY

Registration cancellation must be received by Monday, February 23, 2014. A cancellation fee of \$100 will be assessed at that time. After this date, cancellation requests cannot be honored and refunds will not be given.

CONTACT INFORMATION

Robin Phillips, Program Coordinator • robin.phillips@duke.edu or 919-668-3532

SPECIAL NEEDS

Duke Urology is committed to making its activities accessible to all individuals. If you are in need of accommodation, please do not hesitate to call and/or submit a description of your needs in writing in order to receive service.

Registration

Duke Urology
A Division of the Department of Surgery

DUMC 3707 • Durham NC 27710
391-8322

LEADING EDGE UROLOGY

47th DUKE UROLOGIC ASSEMBLY and
DUKE UROLOGIC CANCER SYMPOSIUM

March 5 – 8, 2015

REGISTER NOW ONLINE
<http://events.duke.edu/dua2015>

Duke Urology
A Division of the Department of Surgery

Duke Cancer Institute

Duke University School of Medicine

present

LEADING EDGE UROLOGY

47th DUKE UROLOGIC
ASSEMBLY
and
DUKE UROLOGIC
CANCER SYMPOSIUM

March 5 – 8, 2015



Disney's Grand Floridian
Convention Center
Lake Buena Vista, Florida

In partnership with our colleagues in the Duke Cancer Institute, the LEADING EDGE UROLOGY: Duke Urologic Assembly has expanded to include the Duke Urologic Cancer Symposium. This expanded educational conference features lectures by Duke and guest Urologists, Medical Oncologists, and Radiation Oncologists. We have assembled an outstanding roster of national experts, participating in a comprehensive scientific program that encompasses cutting edge updates on the most effective and efficient diagnosis and treatments in the sub-specialties of urology.

Thursday, March 5, 2015	
10:00 am - 5:00 pm REGISTRATION OPEN ALL DAY	
10:00 am - 5:50 pm EXHIBIT HALL OPEN	
Session I	RENAL CELL & UROTHELIAL CARCINOMA
Moderator:	Dan George, MD
1:00 pm	ARMSTRONG: Risk Adapted Systemic Therapy for RCC Including Non-Clear Cell
1:15 pm	GEORGE: New drugs in RCC: Beyond VEGF and mTOR
1:30 pm	RAMPERSAUD: New Biomarkers for High Risk Non-Invasive TCC
1:50 pm	INMAN: Optimal Perioperative and Operative Care of Urothelial Carcinoma
2:10 pm	EATON: Robotic Surgery for Renal Cell Carcinoma-Controversies
2:30 pm	LEE & INMAN: Point/Counterpoint Radiation vs. Surgery for Metastatic Seminoma for the 3cm Post-Chemotherapy Retroperitoneal Mass
3:00 pm	BREAK IN THE EXHIBIT HALL
Session II	MULTIDISCIPLINARY CARE FOR MEN WITH LOCALIZED PROSTATE CANCER
Moderator:	Andrew Armstrong, MD
3:15 pm	LEE: The Role of Brachytherapy for Prostate Cancer
3:35 pm	POLASCIK: Integration of MRI in the Active Surveillance and Focal Therapy Paradigm
3:55 pm	LEE: Hypofractionation for Prostate Cancer
4:15 pm	POLASCIK: Active Surveillance Vs Radical Prostatectomy for Low and Intermediate Risk Prostate Cancer
4:35 pm	EATON: Technical Considerations of Robotic Prostatectomy
4:55 pm	PATIERNO: Population Genomics of Prostate Cancer: Novel Pathways for Tumor Aggressiveness and Translational Interventions
5:15 pm	Case Presentations
5:45 pm	Adjourn
6:00 pm	WELCOME RECEPTION

Friday, March 6, 2014	
6:30 - 7:30 am REGISTRATION/BREAKFAST IN THE EXHIBIT HALL	
Session III	GENITOURINARY ONCOLOGY
Moderator:	Brant Inman, MD
7:00 am	LEDER/ROBERTSON Evaluation of Adrenal Masses: Imaging and Biochemical Characterization Guides to Therapy
7:20 am	WALTHER: Managing Lymphatic Injury During Oncologic Surgery
7:40 am	LEDER/ROBERTSON: Imaging of systemic GU malignancy: what’s new in 2015?
8:00 am	VIEWEG: Basic principles of immuno-therapy: is PD-1 the new pathway of choice?
8:20 am	ROBERTSON: – Is there still a role for HIFU in Prostate Cancer?
8:40 am	SCARDINO: Should we still screen men for Prostate Cancer with PSA?
9:00 am	PATIERNO: Prostate Cancer Disparities from Cells to Society: Social Determinants and Effective Interventions
9:30 am	RAMPERSAUD & POLASCIK: Point/Counter Point-Extirpative vs Ablative Therapy of Small RCC
10:00 am	BREAK IN THE EXHIBIT HALL
Session IV	SYSTEMATIC APPROACHES TO PROSTATE CANCER
Moderator:	David Paulson, MD
10:15 am	FERRANDINO: Care for the Man with a Rising PSA
10:35 am	VIEWEG: Cost of Active Surveillance for Prostate Cancer- an Economic Analysis
11:55 am	ARMSTRONG: Systemic Therapy and Sequencing for Metastatic Prostate Cancer
11:15 am	GEORGE: New Drugs in CRPC: The 2015 Horizon
11:35 am	PETERSON: Prostate Cancer Survivorship: Role of the Urologist and Team Integration

11:55 am	VICTOR A. POLITANO LECTURESHIP
	RADICAL PROSTATECTOMY: Open, Laparoscopic, or Robotic Assisted?
	PETER T. SCARDINO, MD
12:30 pm	Adjourn
12:45 pm	VICTOR A POLITANO LUNCHEON

Saturday, March 7, 2014	
6:30 - 7:30 am REGISTRATION/BREAKFAST IN THE EXHIBIT HALL	
Session V	CRITICAL KNOWLEDGE FOR UROLOGISTS
Moderator:	Philip Walther, MD
7:00 am	LEDER: Genitourinary Trauma Imaging
7:20 am	WALTHER: Thromboembolism Prophylaxis: State of the Art
7:40 am	DAHM: Better Surgical Innovation in Urology: The Ideal Recommendations
8:00 am	LENTZ: The Urologists Role in Promoting Male Wellness
8:20 am	DAHM: Keeping up with the Best Evidence: Strategies for the Busy Urologist
8:40 am	VIVIANO: Testosterone Replacement Therapy
9:00 am	VIVIANO: Non Testosterone Androgen Replacement
9:20 am	FERRAGAMO: Urology Coding Update – Maximize Reimbursement While Reducing Errors
9:50 am	Panel Discussion
10:00 am	BREAK IN THE EXHIBIT HALL
Session VI	RECONSTRUCTIVE & PEDIATRICS
Moderator:	Andrew Peterson, MD
10:15 am	LE: Urinary Retention
10:35 am	PETERSON: Urethral Reconstruction: A Graded Approach to Management
10:55 am	LENTZ: Avoiding Complications and Maximizing Outcomes During IPP Revision
11:15 am	Panel Discussion
11:35 am	LE: Mesh Complications
11:55 am	ROUTH: VUR Update
12:15 am	WIENER: AUA Guidelines for Cryptorchidism
12:35 am	FERRAGAMO: What Can I Do Now To Get Ready Ror ICD-10?
1:05 am	Adjourn

Sunday, March 8, 2014	
6:30 - 7:30 am BREAKFAST IN THE EXHIBIT HALL	
Session VII	STONES & ENDOUROLOGY
Moderator:	Michael Ferrandino, MD
7:00 am	LIPKIN: New Indications for Ureteroscopy
7:20 am	SCALES: Recovery After Stone Surgery or Multi-disp mgt of Hematuria
7:40 am	PREMINGER: Adjunct Medical Therapy for Nephrolithiasis
8:00 am	LIPKIN: Endoscopic Management of UT TCC
8:20 am	FERRANDINO: Lap Management of Nephrolithiasis
8:40 am	PANEL DISCUSION
9:00 am	FERRANDINO: New Therapies for BPH
9:20 am	PREMINGER: Innovations in the Management of Ureteral Calculi
9:40 am	SCALES: Urology Management of the Geriatric Patient
10:00 am	PANEL DISCUSSION
10:20 am	PREMINGER: Case Presentations
11:00 am	CONFERENCE ADJOURNMENT



CME INFORMATION
Emphasis will be placed on diagnostic evaluations, therapeutic options, management of complications, and the use of new technologies that provide leading edge care to patients. Furthermore, discussion topics will focus on the future of this viable surgical specialty, highlighting techniques proven successful at Duke University's state-of-the-art medical center as well as at leading medical centers around the country.
The approximately 120 national healthcare professionals attending this symposium will be engaged through moderated discussions, panel discussions, case presentations, and interactive lectures on the latest evidence-based approaches to managing a wide range of urologic conditions.
This conference is extremely valuable in our continued effort to assist practicing physicians and other health care professionals in the translation, diffusion, and application of evidence-based knowledge to improve patient safety and enhance clinical outcomes.

At the conclusion of this activity, participants should be able to:
• Gain greater proficiency in coding for urologists • Describe the importance for Urologists to take the lead in men’s health issues • Propose a multidisciplinary approach to identifying, preventing, and treating conditions that are most common or specific to men • Distinguish between low-dose rate (LDR) and high-dose rate (HDR) brachytherapy • Distinguish between conventional fractionation and modest/extreme hypo fractionated schedules • Diagnose the patient with urethral stricture, interpret the retrograde urethrogram and choose the appropriate treatment • Recognize indications for endoscopic treatment, surgical treatment and the need for grafting • Review therapeutic options and sequencing of systemic therapies for men with castration resistant prostate cancer and discuss emerging predictive biomarkers for treatment selection • Incorporate advances in imaging to the GU malignancies and trauma into clinical practice • Propose an evidence based approach to managing complex scenarios in penile implant surgery • Enumerate the preoperative, intraoperative, and postoperative nuances to avoid complications and maximize outcomes with penile implant revision • Learn about surgical and post-surgical care of nephrolithiasis • Gain greater understanding of care of the geriatric patient as it impacts urologic interventions • Diagram systemic therapies for management of renal cell carcinoma, including newer agents • Review current treatment guidelines for the treatment of kidney cancer and compare risk-adapted strategies for the optimal approach to systemic therapy • Identify advances in the detection of urothelial carcinoma and perioperative care of patients undergoing surgery • Describe advances in robotic surgical techniques for renal cell carcinoma and prostate cancer • Attain understanding of new AUA guidelines for management of cryptorchidism • Describe the elements, mandates and challenges of providing survivorship care with examples from Urology.

Accreditation
The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide medical education for physicians.

Credit Designation
The Duke University School of Medicine designates this educational activity for a maximum of 19.5 <i>AMA PRA Category 1 credits</i> ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure
The Duke University School of Medicine adheres to ACCME Essential Areas, Standards, and Policies regarding industry support of continuing medical education. Disclosure of the planning committee and faculty's commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

Disclaimer
The information provided at this CME activity is for continuing medical education purposes only and is not meant to substitute the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patients’ medical condition.

2015 LEADING EDGE UROLOGY MEDICAL DIRECTORS	
John S. Wiener, MD Professor of Surgery Associate Professor in Pediatrics Department of Surgery, Division of Urology Duke University Medical Center	Andrew Armstrong, MD, MSc Associate Professor of Medicine Associate Professor in Surgery Department of Medicine, Division of Oncology Duke University Medical Center

2015 Victor A. Politano, MD, LECTURESHIP SPEAKER	
Peter T. Scardino, MD, FACS Chairman, Department of Surgery Memorial Sloan Kettering Cancer Center New York, NY 10065	2015 Victor A. Politano, MD, Lectureship Speaker will be Peter T. Scardino, MD FACS , Chair Department of Surgery, Memorial Sloan Kettering Cancer Center. Dr. Scardino has been a recognized leader in the surgical management of prostate cancer and leads one of the world’s leading centers in urologic oncology. His expertise includes early detection, prognosis, and surgical treatment of prostate cancer.

GUEST FACULTY SPEAKERS	
Phillip Dahm, MD, MD, MHSc, FACS Professor of Urology Vice Chair of Veterans Affairs Univ. of Minnesota Minneapolis, MN	Aaron C. Lentz, MD Assistant Professor of Surgery Duke Department of Surgery, Division of Urology
Michael A. Ferragamo, Jr., MD, FACS Practicing Urologist Coding and Reimbursement Consultant Editor of Urology Coding Alert New York	Michael E. Lipkin, MD Assistant Professor of Surgery Duke Department of Surgery, Division of Urology
Johannes W. Vieweg, MD, FACS Professor of Urology Chair Department of Urology University of Florida Gainesville, FL	Steven R. Patierno, PhD Professor of Medicine Professor in Community and Family Medicine Professor of Pharmacology and Cancer Biology Duke Department of Medicine, Division of Oncology

David F. Paulson, MD Professor Emeritus of Surgery Duke Department of Surgery, Division of Urology

Andrew C. Peterson, MD Associate Professor of Surgery Duke Department of Surgery, Division of Urology
--

Thomas J. Polascik, MD Professor of Surgery Duke Department of Surgery, Division of Urology
--

Glenn M. Preminger, MD Chief, Division of Urologic Surgery James F. Glenn, MD, Professor of Urology Duke Department of Surgery, Division of Urology

Edward N. Rampersaud Jr., MD Assistant Professor of Surgery Duke Department of Surgery, Division of Urology
--

Cary N. Robertson, MD Associate Professor of Surgery Duke Department of Surgery, Division of Urology

Jonathan C. Routh, MD, MPH Assistant Professor of Surgery Assistant Professor in Pediatrics Duke Department of Surgery, Division of Urology

Charles D. Scales Jr., MD, MSHS Assistant Professor of Surgery Duke Department of Surgery, Division of Urology

Charles J. Viviano, MD, PhD Assistant Professor of Surgery Duke Department of Surgery, Division of Urology

Philip J. Walther, MD, PhD, FACS Professor of Surgery Associate Professor of Pathology Duke Department of Surgery, Division of Urology
--